Dopaminergic Therapy of Restless Legs Syndrome

Restless Legs Syndrome

Volumn , Issue , 2009, Pages 238-254

  Silber, Michael H ^a,b   Allen, Richard P ^c,d  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960579129     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-075067518-5.10031-X     Document Type: Chapter

References (116)

1. S Akpinar (1982) Treatment of restless legs syndrome with levodopa plus benserazide [letter]. Arch Neurol 39 739.
2. S Akpinar (1987) Restless legs syndrome treatment with dopaminergic drugs. Clin Neuropharmacol 10 69-79.
3. C von Scheele and V Kempi (1990) Long-term effect of dopaminergic drugs in restless legs. Arch Neurol 47 1223-1224.
4. SL Walker, A Fine and MH Kryger (1996) L-Dopa/carbidopa for nocturnal movement disorders in uremia. Sleep 19 214-218.
5. DB Boivin, J Montplaisir and G Poirier (1989) The effects of L-Dopa on periodic leg movements and sleep organization in narcolepsy. Clin Neuropharmacol 12 339-345.
6. PW Kaplan, RP Allen, DW Buchholz, et al. (1993) A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 16 717-723.
7. J Montplaisir, S Boucher, A Gosselin, et al. (1996) Persistence of repetitive EEG arousals (K-alpha complexes) in RLS patients treated with L-DOPA. Sleep 19 196-199.
8. H Benes, B Kurella, J Kummer, et al. (1999) Rapid onset of action of levodopa in restless legs syndrome: A double-blind, randomized, multicenter, crossover trial. Sleep 22 1073-1081.
9. C Brodeur, J Montplaisir, R Godbout, et al. (1998) Treatment of restless legs syndrome and periodic movements during sleep with l-dopa: A double-blind, controlled study. Neurology 38 1845-1848.
10. V Collado-Seidel, J Kazenwadel, TC Wetter, et al. (1999) A controlled study of additional SR-l-dopa in l-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 52 285-290.
11. C Trenkwalder, H Benes, L Grote, et al. (2007) Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial. Mov Disord 22 696-703.
12. C Trenkwalder, K Stiasny, T Pollmacher, et al. (1995) l-Dopa therapy of uremic and idiopathic restless legs syndrome: A double-blind, crossover trial. Sleep 18 681-688.
13. RP Allen and CJ Earley (1996) Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 19 205-213.
14. PM Becker, AO Jamieson and WD Brown (1993) Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: Response and complications of extended treatment in 49 cases. Sleep 16 713-716.
15. C Guilleminault, M Cetel and P Philip (1993) Dopaminergic treatment of restless legs and rebound phenomenom. Neurology 43 445.
16. J Montplaisir, R Godbout, G Poirier, et al. (1986) Restless legs syndrome and periodic movements in sleep: Physiopathology and treatment with L-dopa. Clin Neuropharmacol 9 456-463.
17. M Saletu, P Anderer, B Hogl, et al. (2003) Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of RR-L-dopa and SR-L-dopa in restless legs syndrome. J Neural Transm 110 611-626.
18. R Sandyk, C Bernick, SM Lee, et al. (1987) L-Dopa in uremic patients with the restless legs syndrome. Int J Neurosci 35 233-235.
19. C Trenkwalder, V Collado Seidel, J Kazenwadel, et al. (2003) One-year treatment with standard and sustained-release levodopa: Appropriate long-term treatment of restless legs syndrome? Mov Disord 18 1184-1189.
20. AS Walters, DE Mandelbaum, DS Lewin, et al. (2000) Dopaminergic therapy in children with restless legs/periodic limb movements in sleep and ADHD. Dopaminergic Therapy Study Group. Pediatr Neurol 22 182-186.
21. CJ Earley and RP Allen (1996) Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 19 801-810.
22. MH Silber, BL Ehrenberg, RP Allen, et al. (2004) An algorithm for the management of restless legs syndrome. Mayo Clin Proc 79 916-922.
23. AS Walters, WA Hening, N Kavey, et al. (1988) A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 24 455-458.
24. CJ Earley, JB Yaffee and RP Allen (1998) Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome. Neurology 51 1599-1602.
25. C Trenkwalder, HP Hundemer, A Lledo, et al. (2004) Efficacy of pergolide in treatment of restless legs syndrome: The PEARLS Study. Neurology 62 1391-1397.
26. TC Wetter, K Stiasny, J Winkelmann, et al. (1999) A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 52 944-950.
27. J Pieta, T Millar, J Zacharias, et al. (1998) Effect of pergolide on restless legs and leg movements in sleep in uremic patients. Sleep 21 617-622.
28. MH Silber, J.W.J. Shepard JW Jr and JA Wisbey (1997) Pergolide in the management of restless legs syndrome: an extended study. Sleep 20 878-882.
29. S Noel, H Korri and JE Vanderheyden (1998) Low dosage of pergolide in the treatment of restless legs syndrome. Acta Neurol Belg 98 52-53.
30. J Staedt, H Hunerjager, E Ruther, et al. (1998) Pergolide: Treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). Long-term follow-up on pergolide. J Neural Transm 105(2-3), 265-268.
31. K Stiasny, TC Wetter, J Winkelmann, et al. (2001) Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology 56 1399-1402.
32. C Trenkwalder, TC Wetter, K Stiasny, et al. (2001) [Restless legs syndrome and periodic limb movements in sleep]. Nervenarzt 72 425-436.
33. J Winkelmann, TC Wetter, K Stiasny, et al. (1998) Treatment of restless leg syndrome with pergolide—An open clinical trial. Mov Disord 13 566-569.
34. J Santamaria, A Iranzo and E Tolosa (2003) Development of restless legs syndrome after dopaminergic treatment in a patient with periodic leg movements in sleep. Sleep Med 4 153-155.
35. P Agarwal, S Fahn and SJ Frucht (2004) Diagnosis and management of pergolide-induced fibrosis. Mov Disord 19 699-704.
36. S Shaunak, A Wilkins, JB Pilling, et al. (1999) Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psychiatry 66 79-81.
37. SK Danoff, ME Grasso, PB Terry, et al. (2001) Pleuropulmonary disease due to pergolide use for restless legs syndrome. Chest 120 313-316.
38. AM Pritchett, JF Morrison, WD Edwards, et al. (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77 1280-1286.
39. DG Baseman, PE O'suilleabhain, SC Reimold, et al. (2004) Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 63 301-304.
40. S Junghanns, JT Fuhrmann, G Simonis, et al. (2006) Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader-blinded monocenter echocardiography study. Mov Disord 2 234-238.
41. Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med, 356:29-38.
42. H Benes, CR Heinrich, MA Ueberall, et al. (2004) Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: Results from an open-label 6-month clinical trial. Sleep 27 674-682.
43. K Stiasny, J Robbecke, P Schuler, et al. (2000) Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline—An open clinical trial. Sleep 23 349-354.
44. M Zucconi, A Oldani, C Castronovo, et al. (2003) Cabergoline is an effective single-drug treatment for restless legs syndrome: Clinical and actigraphic evaluation. Sleep 26 815-818.
45. K Stiasny-Kolster, H Benes, I Peglau, et al. (2004) Effective cabergoline treatment in idiopathic restless legs syndrome. Neurology 63 2272-2279.
46. The International Restless Legs Syndrome Study Group (2003) Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4 121-132.
47. WH Oertel, H Benes, R Bodenschatz, et al. (2006) Efficacy of cabergoline in restless legs syndrome: A placebo-controlled study with polysomnography (CATOR). Neurology 67 1040-1046.
48. J Horvath, RD Fross, G Kleiner-Fisman, et al. (2004) Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. Mov Disord 19 656-662.
49. SC Ling, JD Wilkinson, AS Hollman, et al. (1999) The evolution of liver disease in cystic fibrosis. Arch Dis Child 81 129-132.
50. M Yamamoto, T Uesugi and T Nakayama (2007) Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 67 1225-1229.
51. F Tergau, S Wischer, C Wolf, et al. (2001) Treatment of restless legs syndrome with the dopamine agonist alpha-dihydroergocryptine. Mov Disord 16 731-735.
52. H Benes, A Deissler, A Rodenbeck, et al. (2006) Lisuride treatment of restless legs syndrome: First studies with monotherapy in de novo patients and in combination with levodopa in advanced disease. J Neural Transm 113 87-92.
53. H Benes, B Högl, F Palla and R Kohnen (2007) Transdermal lisuride provides early and sustained improvement in quality of sleep and daytime tiredness in RLS patients [abstract]. Sleep Med 8 S58.
54. K Sonka, M Pretl and K Kranda (2003) Management of restless legs syndrome by the partial D2-agonist terguride. Sleep Med 4 455-457.
55. WH Oertel, H Benes, D Garcia-Borreguero, et al. (2008) Efficacy of rotigotine transdermal system in severe restless legs syndrome: A randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 9 228-239.
56. C Trenkwalder, K Stiasny-Kolster, A Kupsch, et al. (2006) Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord 21 1404-1410.
57. M Partinen, K Hirvonen, L Jama, et al. (2006) Efficacy and safety of pramipexole in idiopathic restless legs syndrome: A polysomnographic dose-finding study—The PRELUDE study. Sleep Med 7 407-417.
58. L Ferini-Strambi (2002) Restless legs syndrome augmentation and pramipexole treatment. Sleep Med 3(suppl), S23-S25.
59. SC Lin, J Kaplan, CD Burger, et al. (1998) Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clin Proc 73 497-500.
60. J Montplaisir, R Denesle and D Petit (2000) Pramipexole in the treatment of restless legs syndrome: A follow-up study. Eur J Neurol 7(supp. 1), 27-31.
61. W Ondo, J Romanyshyn, KD Vuong, et al. (2004) Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 61 1393-1397.
62. MH Silber, M Girish and R Izurieta (2003) Pramipexole in the management of restless legs syndrome: An extended study. Sleep 26 819-821.
63. K Stiasny, JC Moller and WH Oertel (2000) Safety of pramipexole in patients with restless legs syndrome. Neurology 55 1589-1590.
64. K Stiasny-Kolster and WH Oertel (2004) Low-dose pramipexole in the management of restless legs syndrome. An open label trial. Neuropsychobiology 50 65-70.
65. JW Winkelman and L Johnston (2004) Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 5 9-14.
66. J Montplaisir, ML Fantini, A Desautels, et al. (2006) Long-term treatment with pramipexole in restless legs syndrome. Eur J Neurol 13 1306-1311.
67. EK Tan and W Ondo (2000) Clinical characteristics of pramipexole-induced peripheral edema. Arch Neurol 57 729-732.
68. S Frucht, JD Rogers, PE Greene, et al. (1999) Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52 1908-1910.
69. S Paus, HM Brecht, J Koster, et al. (2003) Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 18 659-667.
70. I Arnulf (2005) Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 9 185-200.
71. R Allen, PM Becker, R Bogan, et al. (2004) Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 27 907-914.
72. C Trenkwalder, D Garcia-Borreguero, P Montagna, et al. (2004) Ropinirole in the treatment of restless legs syndrome: Results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 75 92-97.
73. AS Walters, WG Ondo, T Dreykluft, et al. (2004) Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: A 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 19 1414-1423.
74. CH Adler, et al. (2004) Ropinirole for restless legs syndrome: A placebo-controlled crossover trial. Neurology 62 1405-1407.
75. MT Pellecchia, C Vitale, M Sabatini, et al. (2004) Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: An open randomized crossover trial versus levodopa sustained release. Clin Neuropharmacol 27 178-181.
76. B Saletu, G Gruber, M Saletu, et al. (2000) Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology 41 181-189.
77. M Saletu, P Anderer, B Saletu, et al. (2000) Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals and respiratory variables. Neuropsychobiology 41 190-199.
78. S Happe, C Sauter, G Klosch, et al. (2003) Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology 48 82-86.
79. E Estivill and V de la Fuente (1999) The efficacy of ropinirole in the treatment of chronic insomnia secondary to restless legs syndrome: Polysomnography data. Rev Neurol 29 805-807.
80. E Estivill and V de la Fuente (1999) Uso de ropinirol como tratamientodel síndrome de piernas inquieta. Rev Neurol 28 962-963.
81. N Galvez-Jimenez and T Khan (1999) Ropinirole and restless legs syndrome. Mov Disord 14 890-892.
82. W Ondo (1999) Ropinirole for restless legs syndrome. Mov Disord 14 138-140.
83. VG Evidente (2001) Piribedil for restless legs syndrome: A pilot study. Mov Disord 16 579-581.
84. K Stiasny-Kolster, R Kohnen, E Schollmayer, et al. (2004) Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: A double-blind, placebo-controlled pilot study. Mov Disord 19 1432-1438.
85. Y Inoue, H Mitani, K Nanba, et al. (1999) Treatment of periodic leg movement disorder and restless leg syndrome with talipexole. Psychiatry Clin Neurosci 53 283-285.
86. VG Evidente, CH Adler, JN Caviness, et al. (2000) Amantadine is beneficial in restless legs syndrome. Mov Disord 15 324-327.
87. M Grewal, R Hawa and C Shapiro (2002) Treatment of periodic limb movements in sleep with selegiline HCl. Mov Disord 17 398-401.
88. AL Chesson Jr, M Wise, D Davila, et al. (1999) Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 22 961-968.
89. W Hening, R Allen, C Earley, et al. (1999) The treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Review. Sleep 22 970-999.
90. WA Hening, RP Allen, CJ Earley, et al. (2004) An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 27 560-583.
91. MR Littner, C Kushida, WM Anderson, et al. (2004) Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 27 557-559.
92. L Vignatelli, M Billiard, P Clarenbach, et al. (2006) EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 13 1049-1065.
93. CJ Earley and RP Allen (2006) Restless legs syndrome augmentation associated with tramadol. Sleep Med 7 592-593.
94. R Vetrugno, C.D La Morgia, R Angelo, et al. (2007) Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord 22 424-427.
95. RP Allen, D Picchietti, WA Hening, et al. (2003) Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4 101-119.
96. D Garcia-Borreguero, RP Allen, R Kohnen, et al. (2007) Diagnostic standards for dopaminergic augmentation of restless legs syndrome: Report from a World Association of Sleep Medicine—International Restless Legs Syndrome Study Group Consensus Conference at the Max Planck Institute. Sleep Med 8 520-530.
97. D Garcia-Borreguero, R Kohnen, B Hogl, et al. (2007) Validation of the Augmentation Severity Rating Scale (ASRS): A multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 8 455-463.
98. B Högl, D Garcia Borreguero, V Gschliesser, et al. (2005) On the development of the “Structured Interview for Diagnosis of Augmentation during RLS treatment” (RLS-SIDA): First experiences [abstract]. Sleep 6(supp. 2),
99. C Bassetti, S Clavadetscher, M Gugger, et al. (2002) Pergolide-associated ‘sleep attacks’ in a patient with restless legs syndrome. Sleep Med 3 275-277.
100. A Gelevert and J de Groen (2003) Restless legs syndrome: Excessive daytime sleepiness caused by dopamine-agonists. Sleep 26 A329-A330.
101. B Saletu, P Anderer, M Saletu, et al. (2002) EEG mapping, psychometric, and polysomnographic studies in restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) patients as compared with normal controls. Sleep Med 3(suppl), S35-S42.
102. JC Moller, Y Korner, W Cassel, et al. (2006) Sudden onset of sleep and dopaminergic therapy in patients with restless legs syndrome. Sleep Med 7 333-339.
103. MJ Nirenberg and C Waters (2006) Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 21 524-529.
104. ML Dodd, KJ Klos, JH Bower, et al. (2005) Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62 1377-1381.
105. V Voon, K Hassan and M Zurowski (2006) Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66 1750-1752.
106. V Voon, K Hassan, M Zurowski, et al. (2006) Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67 1254-1257.
107. M Tippmann-Peikert, MH Silber, JP Park, et al. (2007) Pathologic gambling in patients with restless legs syndrome treated with dopaminergic agonists. Neurology 68 301-303.
108. Quickfall J, Suchowersky O. Pathological gambling associated with dopamine agonist use in restless legs syndrome. Parkinsonism Relat Disord 2007;13:535-536.
109. PM Becker, W Ondo and D Sharon (1998) Encouraging initial response of restless legs syndrome to pramipexole. Neurology 51 1221-1223.
110. H Benes (2006) Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome. Sleep Med 7 31-35.
111. WH Oertel, K Stiasny-Kolster, B Bergtholdt, et al. (2007) Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 22 213-219.
112. M.H Silber, JW Shepard Jr and JA Wisbey (1997) Pergolide in the management of restless legs syndrome: an extended study. Sleep 20 878-882.
113. C Trenkwalder, U Brandenburg, H Hundemer, et al. (2001) A randomized long-term placebo-controlled multicenter trial of pergolide in the treatment of restless legs syndrome with central evaluation of polysomnographic data. Neurology 58 A5.
114. C von Scheele (1986) Levodopa in restless legs. Lancet 2 426-427.
115. JW Winkelman, KD Sethi, CA Kushida, et al. (2006) Efficacy and safety of pramipexole in restless legs syndrome. Neurology 67 1034-1039.
116. R Zanettini, A Antonini, G Gatto, et al. (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 365 39-46.